

S N Lo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/44348/publications.pdf>

Version: 2024-02-01

187
papers

9,603
citations

61984

43
h-index

42399

92
g-index

192
all docs

192
docs citations

192
times ranked

11508
citing authors

#	ARTICLE	IF	CITATIONS
1	Residual melanoma in wide local excision specimens after "complete"™ excision of primary cutaneous in situ and invasive melanomas. <i>Pathology</i> , 2022, 54, 71-78.	0.6	2
2	FDG-PET to predict long-term outcome from anti-PD-1 therapy in metastatic melanoma. <i>Annals of Oncology</i> , 2022, 33, 99-106.	1.2	15
3	Adaptive designs for clinical trials have potential advantages, but statistical challenges lurk!. <i>British Journal of Dermatology</i> , 2022, 186, 205-206.	1.5	2
4	Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis. <i>European Journal of Cancer</i> , 2022, 162, 22-33.	2.8	28
5	Competing risks analysis with missing cause-of-failure"penalized likelihood estimation of cause-specific Cox models. <i>Statistical Methods in Medical Research</i> , 2022, , 096228022110702.	1.5	0
6	The progressive relationship between increasing Breslow thickness and decreasing survival is lost in patients with ultrathick melanomas (≥15mm in thickness). <i>Journal of the American Academy of Dermatology</i> , 2022, 87, 298-305.	1.2	3
7	Clinical Models to Define Response and Survival With Anti"PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2022, 40, 1068-1080.	1.6	43
8	Clinicopathological characteristics of new primary melanomas in patients receiving immune checkpoint inhibitor therapy for metastatic melanoma. <i>Australasian Journal of Dermatology</i> , 2022, 63, .	0.7	1
9	Effect of the time interval between melanoma diagnosis and sentinel node biopsy on the size of metastatic tumour deposits in node-positive patients. <i>European Journal of Cancer</i> , 2022, 167, 133-141.	2.8	3
10	Protocol for the implementation of a stepped-care model to address fear of cancer recurrence in patients previously diagnosed with early-stage (O"II) melanoma. <i>BMJ Open</i> , 2022, 12, e054337.	1.9	2
11	Time interval between diagnostic excision-biopsy of a primary melanoma and sentinel node biopsy: effects on the sentinel node positivity rate and survival outcomes. <i>European Journal of Cancer</i> , 2022, 167, 123-132.	2.8	4
12	Targeting the neonatal Fc receptor in pemphigus: safety first. <i>British Journal of Dermatology</i> , 2022, 186, 389-390.	1.5	1
13	Effect of the <sc>SunSafe</sc> Training Program on the attitudes, knowledge, and behaviour of Australian high school students towards sun safety: a prospective study. <i>Clinical and Experimental Dermatology</i> , 2022, , .	1.3	0
14	Penalized likelihood estimation of a mixture cure Cox model with partly interval censoring"An application to thin melanoma. <i>Statistics in Medicine</i> , 2022, , .	1.6	2
15	Evaluation of the Indications for Sentinel Node Biopsy in Early-Stage Melanoma with the Advent of Adjuvant Systemic Therapy: An International, Multicenter Study. <i>Annals of Surgical Oncology</i> , 2022, 29, 5937-5945.	1.5	4
16	Sensitivity of two Australian melanoma risk tools to identify high"risk individuals among people presenting with their first primary melanoma. <i>Australasian Journal of Dermatology</i> , 2022, , .	0.7	0
17	Higher proportions of CD39+ tumor-resident cytotoxic T cells predict recurrence-free survival in patients with stage III melanoma treated with adjuvant immunotherapy. , 2022, 10, e004771.		16
18	Single-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma: an international, retrospective, cohort study. <i>Annals of Oncology</i> , 2022, 33, 968-980.	1.2	22

#	ARTICLE	IF	CITATIONS
19	The Association Between Excision Margins and Local Recurrence in 1407 Patients with Primary In Situ Melanomas. <i>JAAD International</i> , 2022, , .	2.2	2
20	A tool to predict survival outcomes and guide adjuvant immunotherapy recommendations for patients with stage II melanoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, e21556-e21556.	1.6	0
21	A biomarker-guided Bayesian response-adaptive phase II trial for metastatic melanoma: The Personalized Immunotherapy Platform (PIP) trial design.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS9599-TPS9599.	1.6	0
22	Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanoma. , 2022, 10, e004610.		6
23	FRAME: Familial Risk Assessment of Melanomaâ€”a risk prediction tool to guide CDKN2A germline mutation testing in Australian familial melanoma. <i>Familial Cancer</i> , 2021, 20, 231-239.	1.9	6
24	Prognostic significance of postsurgery circulating tumor <scp>DNA</scp> in nonmetastatic colorectal cancer: Individual patient pooled analysis of three cohort studies. <i>International Journal of Cancer</i> , 2021, 148, 1014-1026.	5.1	77
25	Clinical outcomes following surgical treatment of lentigo maligna of the head and neck. <i>European Journal of Surgical Oncology</i> , 2021, 47, 1145-1151.	1.0	5
26	Predicting recurrence in patients with sentinel node-negative melanoma: validation of the EORTC nomogram using population-based data. <i>British Journal of Surgery</i> , 2021, 108, 550-553.	0.3	7
27	Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition. , 2021, 9, e001931.		46
28	Association of Histologic Regression With a Favorable Outcome in Patients With Stage 1 and Stage 2 Cutaneous Melanoma. <i>JAMA Dermatology</i> , 2021, 157, 166.	4.1	21
29	Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC). <i>Nature Medicine</i> , 2021, 27, 301-309.	30.7	218
30	Sentinel node biopsy in patients with melanoma improves the accuracy of staging when added to clinicopathological features of the primary tumor. <i>Annals of Oncology</i> , 2021, 32, 375-383.	1.2	25
31	Development and Validation of Nomograms to Predict Local, Regional, and Distant Recurrence in Patients With Thin (T1) Melanomas. <i>Journal of Clinical Oncology</i> , 2021, 39, 1243-1252.	1.6	28
32	A multicentre study of naevusâ€”associated melanoma vs. <i>de novo</i> melanoma, tumour thickness and body site differences*. <i>British Journal of Dermatology</i> , 2021, 185, 101-109.	1.5	13
33	An electronic decision supportâ€”based complex intervention to improve management of cardiovascular risk in primary health care: a cluster randomised trial (INTEGRATE). <i>Medical Journal of Australia</i> , 2021, 214, 420-427.	1.7	7
34	Predicting sentinel node positivity in patients with melanoma: external validation of a riskâ€”prediction calculator (the Melanoma Institute Australia nomogram) using a large European populationâ€”based patient cohort*. <i>British Journal of Dermatology</i> , 2021, 185, 412-418.	1.5	14
35	Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study. <i>Lancet Oncology</i> , The, 2021, 22, 836-847.	10.7	104
36	Pathological response and tumour bed histopathological features correlate with survival following neoadjuvant immunotherapy in stage III melanoma. <i>Annals of Oncology</i> , 2021, 32, 766-777.	1.2	22

#	ARTICLE	IF	CITATIONS
37	Surgical excision margins in primary cutaneous melanoma: A systematic review and meta-analysis. <i>European Journal of Surgical Oncology</i> , 2021, 47, 1558-1574.	1.0	7
38	Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma. <i>Annals of Oncology</i> , 2021, 32, 917-925.	1.2	76
39	Histological regression in melanoma: impact on sentinel lymph node status and survival. <i>Modern Pathology</i> , 2021, 34, 1999-2008.	5.5	16
40	Hyperacute toxicity with combination ipilimumab and anti-PD1 immunotherapy. <i>European Journal of Cancer</i> , 2021, 153, 168-178.	2.8	14
41	Re-defining the role of surgery in the management of patients with oligometastatic stage IV melanoma in the era of effective systemic therapies. <i>European Journal of Cancer</i> , 2021, 153, 8-15.	2.8	1
42	Survival Outcomes of Salvage Metastasectomy After Failure of Modern-Era Systemic Therapy for Melanoma. <i>Annals of Surgical Oncology</i> , 2021, 28, 6109-6123.	1.5	8
43	Re-induction ipilimumab following acquired resistance to combination ipilimumab and anti-PD-1 therapy. <i>European Journal of Cancer</i> , 2021, 153, 213-222.	2.8	7
44	Impact of personal genomic risk information on melanoma prevention behaviors and psychological outcomes: a randomized controlled trial. <i>Genetics in Medicine</i> , 2021, 23, 2394-2403.	2.4	22
45	Tumour gene expression signature in primary melanoma predicts long-term outcomes. <i>Nature Communications</i> , 2021, 12, 1137.	12.8	33
46	MULTIPLE ways to correct for MULTIPLE comparisons in MULTIPLE types of studies. <i>British Journal of Dermatology</i> , 2021, 185, 1081-1083.	1.5	10
47	Benefits of a brief psychological intervention targeting fear of cancer recurrence in people at high risk of developing another melanoma: 12-month follow-up results of a randomized controlled trial. <i>British Journal of Dermatology</i> , 2020, 182, 860-868.	1.5	13
48	Site-specific response patterns, pseudoprogression, and acquired resistance in patients with melanoma treated with ipilimumab combined with anti-PD-1 therapy. <i>Cancer</i> , 2020, 126, 86-97.	4.1	113
49	A risk prediction model for the development of subsequent primary melanoma in a population-based cohort. <i>British Journal of Dermatology</i> , 2020, 182, 1148-1157.	1.5	28
50	Combined ipilimumab and nivolumab first-line and after BRAF-targeted therapy in advanced melanoma. <i>Pigment Cell and Melanoma Research</i> , 2020, 33, 358-365.	3.3	51
51	Estimated risk of progression of lentigo maligna to lentigo maligna melanoma. <i>Melanoma Research</i> , 2020, 30, 193-197.	1.2	32
52	Reappraisal of the prognostic significance of mitotic rate supports its reincorporation into the melanoma staging system. <i>Cancer</i> , 2020, 126, 4717-4725.	4.1	14
53	Tumor Mutation Burden and Structural Chromosomal Aberrations Are Not Associated with T-cell Density or Patient Survival in Acral, Mucosal, and Cutaneous Melanomas. <i>Cancer Immunology Research</i> , 2020, 8, 1346-1353.	3.4	13
54	Clinicopathological characteristics and management of colitis with anti-PD1 immunotherapy alone or in combination with ipilimumab. , 2020, 8, e001488.		22

#	ARTICLE	IF	CITATIONS
55	Predicting Sentinel Node Status in Patients With Melanoma: Does Gene Expression Profiling Improve Accuracy?. JCO Precision Oncology, 2020, 4, 990-991.	3.0	2
56	Primary dermal melanoma: clinical behaviour, prognosis and treatment. European Journal of Surgical Oncology, 2020, 46, 2131-2139.	1.0	5
57	Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy†. Annals of Oncology, 2020, 31, 1075-1082.	1.2	62
58	Improved Risk Prediction Calculator for Sentinel Node Positivity in Patients With Melanoma: The Melanoma Institute Australia Nomogram. Journal of Clinical Oncology, 2020, 38, 2719-2727.	1.6	84
59	Author response to: Comment on: External validation of a prognostic model to predict survival of patients with sentinel node-negative melanoma. British Journal of Surgery, 2020, 107, 616-616.	0.3	0
60	The Melanoma Genomics Managing Your Risk Study randomised controlled trial: statistical analysis plan. Trials, 2020, 21, 594.	1.6	5
61	The prognostic significance of microsatellites in cutaneous melanoma. Modern Pathology, 2020, 33, 1369-1379.	5.5	13
62	Cumulative Incidence and Predictors of CNS Metastasis for Patients With American Joint Committee on Cancer 8th Edition Stage III Melanoma. Journal of Clinical Oncology, 2020, 38, 1429-1441.	1.6	23
63	Ipilimumab (IPI) alone or in combination with anti-PD-1 (IPI+PD1) in patients (pts) with metastatic melanoma (MM) resistant to PD1 monotherapy.. Journal of Clinical Oncology, 2020, 38, 10005-10005.	1.6	26
64	Same-day or next-day sentinel node biopsy after lymphoscintigraphy for melanoma using Tc-labelled antimony sulphide colloid. British Journal of Surgery, 2020, 107, 1773-1779.	0.3	1
65	Whole brain radiotherapy (WBRT) after local treatment of brain metastases in melanoma patients: Statistical Analysis Plan. Trials, 2019, 20, 477.	1.6	4
66	Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets. Nature Communications, 2019, 10, 3163.	12.8	205
67	External validation of a prognostic model to predict survival of patients with sentinel node-negative melanoma. British Journal of Surgery, 2019, 106, 1319-1326.	0.3	5
68	Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. Lancet Oncology, The, 2019, 20, e378-e389.	10.7	155
69	Pragmatic trials: lab meets bedside. British Journal of Dermatology, 2019, 181, 431-433.	1.5	0
70	Phase 3 International Trial of Adjuvant Whole Brain Radiotherapy (WBRT) or Observation (OBS) Following Local Treatment of 1-3 Melanoma Brain Metastases (MBMs). International Journal of Radiation Oncology Biology Physics, 2019, 105, S139-S140.	0.8	0
71	Adjuvant Whole-Brain Radiation Therapy Compared With Observation After Local Treatment of Melanoma Brain Metastases: A Multicenter, Randomized Phase III Trial. Journal of Clinical Oncology, 2019, 37, 3132-3141.	1.6	78
72	Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIBâ€C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial. Lancet Oncology, The, 2019, 20, 961-971.	10.7	126

#	ARTICLE	IF	CITATIONS
73	The survivorship experience for patients with metastatic melanoma on immune checkpoint and BRAF-MEK inhibitors. <i>Journal of Cancer Survivorship</i> , 2019, 13, 503-511.	2.9	31
74	Effects of pulsed low-frequency magnetic field therapy on pain intensity in patients with musculoskeletal chronic low back pain: study protocol for a randomised double-blind placebo-controlled trial. <i>BMJ Open</i> , 2019, 9, e024650.	1.9	8
75	Pre-operative ctDNA predicts survival in high-risk stage III cutaneous melanoma patients. <i>Annals of Oncology</i> , 2019, 30, 815-822.	1.2	77
76	Distinct Clinicopathological and Prognostic Features of Thin Nodular Primary Melanomas: An International Study from 17 Centers. <i>Journal of the National Cancer Institute</i> , 2019, 111, 1314-1322.	6.3	35
77	Incidence, features and management of radionecrosis in melanoma patients treated with cerebral radiotherapy and anti-PD-1 antibodies. <i>Pigment Cell and Melanoma Research</i> , 2019, 32, 553-563.	3.3	28
78	Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy. <i>Cancer Cell</i> , 2019, 35, 238-255.e6.	16.8	547
79	Quality of Life Following Surgical Excision of Early-Stage Melanoma of the Head and Neck. <i>JAMA Dermatology</i> , 2019, 155, 502.	4.1	0
80	Comment on "Prognostic value of sentinel lymph node biopsy according to Breslow thickness for cutaneous melanoma". <i>Journal of the American Academy of Dermatology</i> , 2019, 80, e21-e22.	1.2	1
81	Subungual Melanoma of the Hand. <i>Annals of Surgical Oncology</i> , 2019, 26, 1035-1043.	1.5	28
82	Correlation Between Surgical and Histologic Margins in Melanoma Wide Excision Specimens. <i>Annals of Surgical Oncology</i> , 2019, 26, 25-32.	1.5	21
83	Effect of Intensive Patient Education vs Placebo Patient Education on Outcomes in Patients With Acute Low Back Pain. <i>JAMA Neurology</i> , 2019, 76, 161.	9.0	101
84	Primary anorectal melanoma: clinical, immunohistology and DNA analysis of 43 cases. <i>Pathology</i> , 2019, 51, 39-45.	0.6	25
85	Sentinel lymph node biopsy remains the most accurate method of obtaining staging and prognostic information for patients with primary cutaneous melanomas. <i>Australasian Journal of Dermatology</i> , 2019, 60, 75-76.	0.7	1
86	Phase 3 international trial of adjuvant whole brain radiotherapy (WBRT) or observation (Obs) following local treatment of 1-3 melanoma brain metastases (MBMs).. <i>Journal of Clinical Oncology</i> , 2019, 37, 9500-9500.	1.6	3
87	A multicenter analysis of melanoma recurrence following adjuvant anti-PD1 therapy.. <i>Journal of Clinical Oncology</i> , 2019, 37, 9502-9502.	1.6	6
88	Pathological response and survival with neoadjuvant therapy in melanoma: A pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 9503-9503.	1.6	34
89	A phase II, open label, randomized controlled trial of nivolumab plus ipilimumab with stereotactic radiotherapy versus ipilimumab plus nivolumab alone in patients with melanoma brain metastases (ABC-X Trial).. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS9600-TPS9600.	1.6	16
90	Renal replacement therapy intensity for acute kidney injury and recovery to dialysis independence: a systematic review and individual patient data meta-analysis. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, 1017-1024.	0.7	32

#	ARTICLE	IF	CITATIONS
91	Metastasis-specific patterns of response and progression with anti-PD-1 treatment in metastatic melanoma. <i>Pigment Cell and Melanoma Research</i> , 2018, 31, 404-410.	3.3	34
92	Association Between Circulating Tumor DNA and Pseudoprogression in Patients With Metastatic Melanoma Treated With Anti-Programmed Cell Death 1 Antibodies. <i>JAMA Oncology</i> , 2018, 4, 717.	7.1	229
93	Survival and prognostic factors for patients with melanoma brain metastases in the era of modern systemic therapy. <i>Pigment Cell and Melanoma Research</i> , 2018, 31, 509-515.	3.3	34
94	Prognostic Significance of Periadnexal Extension in Cutaneous Melanoma and its Implications for Pathologic Reporting and Staging. <i>American Journal of Surgical Pathology</i> , 2018, 42, 359-366.	3.7	11
95	Long-Term Survival of Patients with Thin (T1) Cutaneous Melanomas: A Breslow Thickness Cut Point of 0.8mm Separates Higher-Risk and Lower-Risk Tumors. <i>Annals of Surgical Oncology</i> , 2018, 25, 894-902.	1.5	69
96	Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. <i>Lancet Oncology</i> , The, 2018, 19, 672-681.	10.7	732
97	Reply to M. Horiguchi et al. <i>Journal of Clinical Oncology</i> , 2018, 36, 722-723.	1.6	2
98	The survivorship experience of patients with metastatic melanoma on long-term immune checkpoint inhibitors. <i>Annals of Oncology</i> , 2018, 29, ix105.	1.2	0
99	ASO Author Reflections: Long-Term Survival of Patients with Thin (T1) Cutaneous Melanomas. <i>Annals of Surgical Oncology</i> , 2018, 25, 918-919.	1.5	1
100	Rheumatic immune-related adverse events secondary to anti-programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: A case series. <i>European Journal of Cancer</i> , 2018, 105, 88-102.	2.8	53
101	Combined ipilimumab and nivolumab first-line and after BRAF-directed targeted therapies in advanced melanoma patients. <i>Annals of Oncology</i> , 2018, 29, viii448.	1.2	1
102	Communities driving change: evaluation of an Aboriginal driver licensing programme in Australia. <i>Health Promotion International</i> , 2018, 33, 925-937.	1.8	7
103	The melanoma genomics managing your risk study: A protocol for a randomized controlled trial evaluating the impact of personal genomic risk information on skin cancer prevention behaviors. <i>Contemporary Clinical Trials</i> , 2018, 70, 106-116.	1.8	19
104	1 Versus 2-cm Excision Margins for pT2-pT4 Primary Cutaneous Melanoma (MelMarT): A Feasibility Study. <i>Annals of Surgical Oncology</i> , 2018, 25, 2541-2549.	1.5	35
105	The ABC of reporting statistical analyses in theBJD: Always Be Clear. <i>British Journal of Dermatology</i> , 2018, 179, 3-5.	1.5	1
106	Quality assurance analysis of hippocampal avoidance in a melanoma whole brain radiotherapy randomized trial shows good compliance. <i>Radiation Oncology</i> , 2018, 13, 132.	2.7	6
107	Research Techniques Made Simple: Sample Size Estimation and Power Calculation. <i>Journal of Investigative Dermatology</i> , 2018, 138, 1678-1682.	0.7	57
108	FDG-PET response and outcome from anti-PD-1 therapy in metastatic melanoma. <i>Annals of Oncology</i> , 2018, 29, 2115-2120.	1.2	131

#	ARTICLE	IF	CITATIONS
109	Sustained long-term benefits of a psycho-educational intervention targeting fear of cancer recurrence in people at high risk of developing another melanoma: A randomised controlled trial.. Journal of Clinical Oncology, 2018, 36, 10082-10082.	1.6	1
110	Utility of 1-year FDG-PET (PET) to determine outcomes from anti-PD-1 (PD1) based therapy in patients (pts) with metastatic melanoma (MM).. Journal of Clinical Oncology, 2018, 36, 9517-9517.	1.6	8
111	Activity of targeted therapy after failure of first-line immunotherapy in BRAF-mutant metastatic melanoma.. Journal of Clinical Oncology, 2018, 36, 9532-9532.	1.6	12
112	The utility of chemotherapy after immunotherapy failure in metastatic melanoma: A multicenter case series.. Journal of Clinical Oncology, 2018, 36, e21588-e21588.	1.6	15
113	Survivorship experience for patients (pts) with metastatic melanoma (MM) on immunotherapy (IT).. Journal of Clinical Oncology, 2018, 36, e21503-e21503.	1.6	0
114	Survivorship experience for patients (pts) with metastatic melanoma (MM) on long-term targeted therapy (TT).. Journal of Clinical Oncology, 2018, 36, 9556-9556.	1.6	0
115	A Trial of Extending Hemodialysis Hours and Quality of Life. Journal of the American Society of Nephrology: JASN, 2017, 28, 1898-1911.	6.1	62
116	Impact of the Alexander technique on well-being: a randomised controlled trial involving older adults with visual impairment. Australasian journal of optometry, The, 2017, 100, 633-641.	1.3	7
117	Extranodal Spread is Associated with Recurrence and Poor Survival in Stage III Cutaneous Melanoma Patients. Annals of Surgical Oncology, 2017, 24, 1378-1385.	1.5	17
118	Survival of patients with melanoma brain metastasis treated with stereotactic radiosurgery and active systemic drug therapies. European Journal of Cancer, 2017, 75, 169-178.	2.8	96
119	Unexpected UVR and non-UVR mutation burden in some acral and cutaneous melanomas. Laboratory Investigation, 2017, 97, 130-145.	3.7	40
120	A randomized, placebo-controlled trial of patient education for acute low back pain (PREVENT Trial): statistical analysis plan. Brazilian Journal of Physical Therapy, 2017, 21, 219-223.	2.5	4
121	A multireferral centre retrospective cohort analysis on the experience in treatment of metastatic uveal melanoma and utilization of sequential liver-directed treatment and immunotherapy. Melanoma Research, 2017, 27, 243-250.	1.2	12
122	Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma. Clinical Cancer Research, 2017, 23, 5024-5033.	7.0	192
123	Analysis of an electrical impedance spectroscopy system in short-term digital dermoscopy imaging of melanocytic lesions. British Journal of Dermatology, 2017, 177, 1432-1438.	1.5	25
124	Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases. British Journal of Cancer, 2017, 116, 1558-1563.	6.4	91
125	Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma. Annals of Oncology, 2017, 28, 1130-1136.	1.2	253
126	Blood flow rate and circuit life in continuous renal replacement therapy (CRRT): a randomised controlled trial (RCT). Australian Critical Care, 2017, 30, 109.	1.3	0

#	ARTICLE	IF	CITATIONS
127	Accurate <i>p</i> -values for adaptive designs with binary endpoints. <i>Statistics in Medicine</i> , 2017, 36, 2643-2655.	1.6	6
128	Faster Blood Flow Rate Does Not Improve Circuit Life in Continuous Renal Replacement Therapy: A Randomized Controlled Trial. <i>Critical Care Medicine</i> , 2017, 45, e1018-e1025.	0.9	22
129	Melanoma diagnosis may be a pitfall for optical coherence tomography assessment of equivocal amelanotic or hypomelanotic skin lesions. <i>British Journal of Dermatology</i> , 2017, 177, 574-577.	1.5	8
130	Conditional Survival: An Assessment of the Prognosis of Patients at Time Points After Initial Diagnosis and Treatment of Locoregional Melanoma Metastasis. <i>Journal of Clinical Oncology</i> , 2017, 35, 1721-1729.	1.6	40
131	A randomized phase II study of nivolumab or nivolumab combined with ipilimumab in patients (pts) with melanoma brain metastases (mets): The Anti-PD1 Brain Collaboration (ABC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 9508-9508.	1.6	98
132	Trends in fall-related ambulance use and hospitalisation among older adults in NSW, 2006-2013: a retrospective, population-based study. <i>Public Health Research and Practice</i> , 2017, 27, .	1.5	12
133	57-Driving change: implementation of a multi-site community licensing program for aboriginal people. <i>Injury Prevention</i> , 2016, 22, A22.2-A22.	2.4	0
134	Low Ambient Temperature and Intracerebral Hemorrhage: The INTERACT2 Study. <i>PLoS ONE</i> , 2016, 11, e0149040.	2.5	15
135	Accuracy of optical coherence tomography for the diagnosis of superficial basal cell carcinoma: a prospective, consecutive, cohort study of 168 cases. <i>British Journal of Dermatology</i> , 2016, 175, 1290-1300.	1.5	48
136	Femoral Access and Delivery of Continuous Renal Replacement Therapy Dose. <i>Blood Purification</i> , 2016, 41, 11-17.	1.8	26
137	Breslow Thickness Measurements of Melanomas Around American Joint Committee on Cancer Staging Cut-Off Points: Imprecision and Terminal Digit Bias Have Important Implications for Staging and Patient Management. <i>Annals of Surgical Oncology</i> , 2016, 23, 2658-2663.	1.5	17
138	Outcome and Prognostic Factors of Stereotactic Radiosurgery (SRS) for Melanoma Brain Metastases (MBM) in Era of Effective Systemic Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, E710-E711.	0.8	0
139	Activity and safety of radiotherapy with anti-PD-1 drug therapy in patients with metastatic melanoma. <i>Oncolmmunology</i> , 2016, 5, e1214788.	4.6	123
140	Debate: adjuvant whole brain radiotherapy or not? More data is the wiser choice. <i>BMC Cancer</i> , 2016, 16, 372.	2.6	14
141	521-Does an on-road motorcycle coaching program reduce crashes in novice riders? A randomised control trial. <i>Injury Prevention</i> , 2016, 22, A188.1-A188.	2.4	0
142	Epidemiology of RBC Transfusions in Patients With Severe Acute Kidney Injury. <i>Critical Care Medicine</i> , 2016, 44, 892-900.	0.9	9
143	Does an on-road motorcycle coaching program reduce crashes in novice riders? A randomised control trial. <i>Accident Analysis and Prevention</i> , 2016, 86, 40-46.	5.7	29
144	3305 PD1 inhibition-induced changes in melanoma and its associated immune infiltrate. <i>European Journal of Cancer</i> , 2015, 51, S666.	2.8	6

#	ARTICLE	IF	CITATIONS
145	Understanding burn injuries in Aboriginal and Torres Strait Islander children: protocol for a prospective cohort study: Table A1. <i>BMJ Open</i> , 2015, 5, e009826.	1.9	14
146	An integrated general practice and pharmacy-based intervention to promote the use of appropriate preventive medications among individuals at high cardiovascular disease risk: protocol for a cluster randomized controlled trial. <i>Implementation Science</i> , 2015, 11, 129.	6.9	7
147	Emergency department clinical redesign, team-based care and improvements in hospital performance: A time series analysis. <i>EMA - Emergency Medicine Australasia</i> , 2015, 27, 317-322.	1.1	16
148	3302 Safety and Activity of Combined Radiotherapy (RT) and Anti-PD-1 Antibodies (PD-1) in Patients (pts) with Metastatic Melanoma. <i>European Journal of Cancer</i> , 2015, 51, S664.	2.8	8
149	Behind the Wheel: Predictors of Driving Exposure in Older Drivers. <i>Journal of the American Geriatrics Society</i> , 2015, 63, 1137-1145.	2.6	22
150	Clinicopathologic features associated with efficacy and long-term survival in metastatic melanoma patients treated with <i>BRAF</i> or combined <i>BRAF</i> and MEK inhibitors. <i>Cancer</i> , 2015, 121, 3826-3835.	4.1	40
151	A Randomized Controlled Trial of Regional Citrate Versus Regional Heparin Anticoagulation for Continuous Renal Replacement Therapy in Critically Ill Adults*. <i>Critical Care Medicine</i> , 2015, 43, 1622-1629.	0.9	146
152	Can the Alexander Technique improve balance and mobility in older adults with visual impairments? A randomized controlled trial. <i>Clinical Rehabilitation</i> , 2015, 29, 244-260.	2.2	22
153	Behind the Wheel. <i>Transportation Research Record</i> , 2015, 2516, 35-43.	1.9	10
154	Effect of a Computer-Guided, Quality Improvement Program for Cardiovascular Disease Risk Management in Primary Health Care. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2015, 8, 87-95.	2.2	98
155	Rational and design of a stepped-wedge cluster randomized trial evaluating quality improvement initiative for reducing cardiovascular events among patients with acute coronary syndromes in resource-constrained hospitals in China. <i>American Heart Journal</i> , 2015, 169, 349-355.	2.7	24
156	Health-related quality of life in survivors of acute kidney injury: The <i>PROLONGED OUTCOMES STUDY</i> of the <i>RENAL</i> randomized <i>EX</i> valuation of <i>N</i> ormal <i>I</i> versus <i>A</i> ugmented <i>L</i> evel <i>RE</i> placement <i>T</i> herapy study outcomes. <i>Nephrology</i> , 2015, 20, 492-498.	1.6	26
157	Change in the Hippocampal Volume After Whole-Brain Radiation Therapy With or Without Hippocampal Avoidance Technique. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, E82.	0.8	2
158	An economic case for a cardiovascular polypill? A cost analysis of the Kanyini GAP trial. <i>Medical Journal of Australia</i> , 2014, 201, 671-673.	1.7	18
159	Daily Protein Intake and Patient Outcomes in Severe Acute Kidney Injury: Findings of the Randomized Evaluation of Normal versus Augmented Level of Replacement Therapy (RENAL) Trial. <i>Blood Purification</i> , 2014, 37, 325-334.	1.8	25
160	Long-Term Survival and Dialysis Dependency Following Acute Kidney Injury in Intensive Care: Extended Follow-up of a Randomized Controlled Trial. <i>PLoS Medicine</i> , 2014, 11, e1001601.	8.4	117
161	Poor Sleep Quality Is Strongly Associated With Subsequent Pain Intensity in Patients With Acute Low Back Pain. <i>Arthritis and Rheumatology</i> , 2014, 66, 1388-1394.	5.6	62
162	Semiparametric methods for multistate survival models in randomised trials. <i>Statistics in Medicine</i> , 2014, 33, 1621-1645.	1.6	1

#	ARTICLE	IF	CITATIONS
163	Timing of Renal Replacement Therapy and Patient Outcomes in the Randomized Evaluation of Normal Versus Augmented Level of Replacement Therapy Study*. Critical Care Medicine, 2014, 42, 1756-1765.	0.9	35
164	The Bidirectional Relationship Between Pain Intensity and Sleep Disturbance/Quality in Patients With Low Back Pain. Clinical Journal of Pain, 2014, 30, 755-765.	1.9	107
165	Hospital Quality Improvement Initiative for Patients With Acute Coronary Syndromes in China. Circulation: Cardiovascular Quality and Outcomes, 2014, 7, 217-226.	2.2	46
166	On the maximum penalized likelihood approach for proportional hazard models with right censored survival data. Computational Statistics and Data Analysis, 2014, 74, 142-156.	1.2	12
167	The Motorcycle Rider Behavior Questionnaire: Psychometric properties and application amongst novice riders in Australia. Transportation Research Part F: Traffic Psychology and Behaviour, 2014, 22, 126-139.	3.7	50
168	Angiotensin-converting enzyme inhibitor usage and acute kidney injury: A secondary analysis of <sc>RENAL</sc> study outcomes. Nephrology, 2014, 19, 617-622.	1.6	16
169	Calorie intake and patient outcomes in severe acute kidney injury: findings from The Randomized Evaluation of Normal vs. Augmented Level of Replacement Therapy (RENAL) study trial. Critical Care, 2014, 18, R45.	5.8	44
170	A trauma quality improvement programme associated with improved patient outcomes: 21 years of experience at an Australian Major Trauma Centre. Injury, 2014, 45, 830-834.	1.7	17
171	Falls in Older people with Cataract, a longitudinal evaluation of impact and risk: the FOCUS study protocol: Table A1. Injury Prevention, 2014, 20, e7-e7.	2.4	12
172	Perceived Value of a Motorcycle Training Program: The Influence of Crash History and Experience of the Training. Traffic Injury Prevention, 2014, 15, 407-413.	1.4	1
173	Choice of renal replacement therapy modality and dialysis dependence after acute kidney injury: a systematic review and meta-analysis. Intensive Care Medicine, 2013, 39, 987-997.	8.2	262
174	Early acid-base and blood pressure effects of continuous renal replacement therapy intensity in patients with metabolic acidosis. Intensive Care Medicine, 2013, 39, 429-436.	8.2	28
175	A randomized trial to evaluate the effectiveness of an individual, education-based safe transport program for drivers aged 75 years and older. BMC Public Health, 2013, 13, 106.	2.9	17
176	Fluid resuscitation with 6% hydroxyethyl starch (130/0.4 and 130/0.42) in acutely ill patients: systematic review of effects on mortality and treatment with renal replacement therapy. Intensive Care Medicine, 2013, 39, 558-568.	8.2	147
177	Sleep-Deprived Young Drivers and the Risk for Crash. JAMA Pediatrics, 2013, 167, 647.	6.2	94
178	The HoneyPot Randomized Controlled Trial Statistical Analysis Plan. Peritoneal Dialysis International, 2013, 33, 426-435.	2.3	9
179	The risk of cancer in people with diabetes and chronic kidney disease. Nephrology Dialysis Transplantation, 2012, 27, 3337-3344.	0.7	31
180	Fluid Resuscitation with 6% Hydroxyethyl Starch (130/0.4) in Acutely Ill Patients. Anesthesia and Analgesia, 2012, 114, 159-169.	2.2	85

#	ARTICLE	IF	CITATIONS
181	An observational study fluid balance and patient outcomes in the randomized evaluation of normal vs. augmented level of replacement therapy trial*. Critical Care Medicine, 2012, 40, 1753-1760.	0.9	776
182	Robust small sample accurate inference in moment condition models. Computational Statistics and Data Analysis, 2012, 56, 3182-3197.	1.2	14
183	Comparison of radiation exposure of trauma patients from diagnostic radiology procedures before and after the introduction of a panscan protocol. EMA - Emergency Medicine Australasia, 2012, 24, 43-51.	1.1	57
184	An adaptive confirmatory trial with interim treatment selection: Practical experiences and unbalanced randomization. Statistics in Medicine, 2011, 30, 1541-1554.	1.6	12
185	Intensity of Continuous Renal-Replacement Therapy in Critically Ill Patients. New England Journal of Medicine, 2009, 361, 1627-1638.	27.0	1,288
186	Robust and accurate inference for generalized linear models. Journal of Multivariate Analysis, 2009, 100, 2126-2136.	1.0	21
187	Saddlepoint approximation for semi-Markov processes with application to a cardiovascular randomised study. Computational Statistics and Data Analysis, 2009, 53, 683-698.	1.2	3